ProCE Banner Activity

Are We Treating HBV Early Enough?


Download this slideset featuring expert perspectives on expanded HBV treatment candidacy for early treatment engagement, including adverse event considerations, cost-effectiveness, and clinical outcomes such as the potential impact on liver disease progression and HCC rates.

Released: February 23, 2024



Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Mark S. Sulkowski

Mark S. Sulkowski, MD, FIDSA, FAASLD

Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC, in partnership with Hepatitis B Foundation

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.


Hepatitis B Foundation

ProCE Banner